Generic Name: doravirine + tenofovir disoproxil fumarate + lamivudine
Other Market Name: N/A
Drug Class: Single-Tablet Regimens
Company: Merck & Company
Approval Status: Experimental
Generic Version Available: No
Experimental Code: MK-1439A
MK-1439A has not yet been reviewed for inclusion in the DHHS list of recommended HIV treatments.
MK-1439A is an experimental HIV medication. It contains three different types of HIV drugs: one non-nucleoside reverse transcriptase inhibitor (NNRTI) and two nucleoside reverse transcriptase inhibitors (NRTIs). It is currently in Phase III clinical trials.
MK-1439A is a single-tablet regimen containing generic versions of two currently approved HIV medications (tenofovir disoproxil fumarate and lamivudine) and one experimental HIV medication (doravirine).
Adult Dose: One tablet once a day. Each tablet contains 100mg doravirine + 300mg tenofovir disoproxil fumarate + 300mg lamivudine.
Pediatric Dose: N/A
Dosing Info: This is a complete one-pill, once-daily drug regimen.
Last Revised: January 24, 2016